← Back to Search

Crosslinking Agent

Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system. for Keratoconus

Phase 2
Waitlist Available
Led By David Lubeck, MD
Research Sponsored by Arbor Center for Eye Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial will test a new device to treat corneal thinning. The goal is to see if it is safe and effective.

Eligible Conditions
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean keratometry in diopters
Secondary outcome measures
Best corrected visual acuity

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Pulsed, acceleratedExperimental Treatment1 Intervention
18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
Group II: ConventionalActive Control1 Intervention
9mW continuous, 10 minutes of illumination.

Find a Location

Who is running the clinical trial?

Arbor Center for Eye CareLead Sponsor
David Lubeck, MDPrincipal InvestigatorArbor Center for Eye Care
~2 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top